ICE Cube commercial COVID-19 experiment

The first COVID-19 drug research in space started operations in the European commercial ICE-Cubes facility in December on the International Space Station. By examining this medicine in microgravity, researcher aim to better understand how Remdesivir interacts with its delivery substance cyclodextrin so that the drug’s efficiency can be improved. This commercial research from Hungarian companies was installed next to other commercial cube experiments that continued to run in the facility.

The experiment represents collaboration at its finest: The customers, InnoStudio and Cyclolab, are using the High Quality Protein Crystal Growth Service Kirara, operated by the Japan Manned Space Systems Corporation (JAMSS), to run an experiment in the ICE Cubes Facility, managed by Space Application Systems, in ESA’s Columbus laboratory.